HIV / AIDS

Investigators used an updated “kick and kill” strategy to expose and eliminate dormant infected cells in HIV-positive mice.

There is a high level of engagement in HIV care observed among pregnant women, which displays a commitment to their health and wellbeing during their pregnancy, the study authors wrote.

The AIDS Clinical Trials Group (ACTG) is beginning stage 2 trials for Triplex, a novel vaccine for people living with HIV and cytomegalovirus (CMV).

By 2030, the US is targeting reducing the number of new HIV infections by 90 percent.

Dolutegravir-based antiretroviral therapy proved more effective than standard treatments for HIV-positive children, reducing treatment failure by 40%.

Investigators compared pre- and post-intervention data points at 4 clinics in Kenya.

Stigma, and a lack of communication and awareness all inhibit HIV PrEP uptake, but digital health and new forms of PrEP are aiming to increase users.

This novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.

The therapy becomes the first injectable approved in the United States for this indication.

Nearly 20% of infants were overweight or obese by 1 year of age regardless of HIV exposure, a new study in South Africa found.

The proposed funding will include a number of measures of spending towards HIV and prevention, including community centers for PrEP education.

A clinical trial of 8 sub-Saharan African countries will be the first to study the efficacy of mRNA COVID-19 vaccination in people living with HIV.

A novel digital pill was 98% effective in tracking daily HIV PrEP adherence.

Community-based models of antiretroviral therapy were as effective as facility-based care in terms of viral suppression, the study authors wrote.

The CDC updated its HIV PrEP guidelines, including a recommendation that doctors talk to all sexually active adults about HIV prevention and prescribe PrEP to anyone who asks for it.

Urban areas in Florida had more social disorganization factors that drove HIV incidence than rural areas.

Merck announced an enrollment pause in 2 of their stage 3 clinical trials for once-monthly oral islatravir for HIV PrEP. Enrolled participants will continue receiving study medicine.

Methamphetamine use and experienced intimate partner violence led to increased HIV viral replication in Black and Latinx men who have sex with men.

Only 1 in 3 heterosexually active adults is aware of HIV PrEP, and this is even lower among Hispanic/Latinx men and women.

Study authors from the CDC found that girls in the sub-Saharan country of Namibia are at increased risk for HIV acquisition and also experience risk factors that make them eligible for HIV infection prevention programs.

Even after it was confirmed safe, women living with HIV are neglecting to use the drug dolutegravir, potentially subjecting them to worse HIV treatment outcomes.

Rates of sustained viral suppression among people living with HIV were lower than expected, especially among children and adolescents.

After the intervention, more patients were correctly prescribed nPEP and more follow-up visits were recommended.

Adding additional screening methods in combination with standard testing would increase diagnostic accuracy for tuberculosis infection among patients living with HIV.

HIV Stakeholders weigh on the future of PrEP.

A study found trans people were not substantively included in many countries’ HIV national strategic plans, despite being disproportionately impacted by HIV/AIDS.

How 1 provider is training medical peers to offer PrEP education and prescribe it.

Bias against injection drug users can inhibit them from receiving potentially lifesaving care, such as HIV pre-exposure prophylaxis (PrEP). Community-based responses like syringe service programs help combat this stigma.

Fenway Health’s Pride in Our Health podcast is an example of new voices being heard, and an alternative means of getting health information to the general public.

Adding genotypic resistance testing (GRT) to routine care did not improve HIV virologic outcomes for patients for whom first-line ART failed, the study authors wrote.